Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zambon launches Xadago first in Germany, next in Switzerland

This article was originally published in Scrip

Executive Summary

Zambon has launched Xadago (safinamide), an add-on therapy for treating idiopathic Parkinson's disease in its first market, Germany. It is the first new chemical entity to be approved for Parkinson's in 10 years.

You may also be interested in...



Breath Therapeutics Snapped Up Post Series A By Specialty Company Zambon

Italy’s privately held Zambon could pay up to 500m to bulk up its respiratory products pipeline, producing a nice return for Breath Therapeutics’ syndicate of European investors.

Constitutional Complaints In Germany Cast Doubt Over Fate Of UPC

The UK’s withdrawal from the EU could upset the Unitary Patent Court project.

Will COVID-19 Drive The Decline Of International Reference Pricing?

International reference pricing has created narrow price corridors that can limit access to medicines and vaccines in lower income countries. The issue will start to impact higher income EU markets if US plans to introduce IRP come to fruition.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel